

Noah C. Goldstein

Counsel

Westborough, MA

T: (508) 948-0492

E: NCGoldstein@pbnlaw.com

Noah Goldstein advises pharmaceutical, biotech, and medical device companies on legal, regulatory, and healthcare compliance matters. As counsel in Porzio, Bromberg & Newman's Life Sciences Legal, Regulatory, and Compliance Practice Group, he provides tailored guidance to support companies at every stage of the product life cycle, from research and development to launch and commercialization.

Noah advises companies of all sizes, including those in the rare disease space and companies with complex products, such as cell and gene therapies. He provides guidance on applicable laws, regulations, and industry guidelines and codes including fraud and abuse laws, the Federal Food, Drug, and Cosmetic Act, FDA and FTC regulations and guidance, OIG guidance, the PhRMA Code, and the AdvaMed Code.

Noah focuses his practice on matters related to interactions and engagements with healthcare professionals, payors, patients, and advocacy organizations, patient support programs, medical affairs and commercial activities and interactions, advertising and promotion, clinical trials, expanded access programs, conflicts of interest, and related privacy considerations. He also helps companies build, operationalize, and assess their healthcare compliance programs.

Noah reviews internal and external company materials and has regularly served as a legal reviewer on materials review committees. He also reviews and prepares trainings, policies and procedures, and contracts. Additionally, he conducts healthcare compliance assessments, formulating compliance action plans that provide a roadmap for addressing key risks.

Noah leans on his past litigation and in-house healthcare compliance experience to provide business-oriented, practical, and risk-focused advice to help clients navigate their unique needs. He enjoys the collaborative and multidisciplinary nature of his work.

Memberships

- American Health Law Association - Member (February 2024 - Present)

News

*No aspect of this or any advertisement has been approved by the Supreme Court of New Jersey. For ranking methodologies, please see **here**.*

- Porzio, Bromberg & Newman Named Winner of Financial Times Innovative Lawyers in Healthcare & Life Sciences Award, 12/05/2023
- Porzio Promotes Noah C. Goldstein, Caitlin M. Nolan, Raquel R. Rivera and Sara R. Simon to Counsel, 7/01/2023
- Noah Goldstein Joins the Massachusetts office of the Life Sciences Team, 7/06/2020

Articles

- Midyear Update on Recent OIG Activity for Life Sciences Legal and Compliance Professionals (Part 2), 7/31/2025
- Midyear Update on Recent OIG Activity for Life Sciences Legal and Compliance Professionals (Part 1), 7/24/2025
- Settlement Renews Focus on Speaker Program Compliance; Complaint Highlights Additional Compliance Considerations, 2/27/2025
- New Year, New Recommendations: FDA Finalizes SIUU Guidance, 1/16/2025
- Clinical Trial Recruitment: Who Are You Paying And What Are You Saying? – *Clinical Leader*, 7/15/2024
- The More Things Change, the More They Stay the Same: Government Scrutiny of Financial Arrangements Continues, 1/18/2024
- OIG's New General Compliance Program Guidance (GCPG): Overview and Takeaways for Life Sciences Companies, 11/17/2023

Speaking Engagements

- “Speaker Programs in 2026: Practical Legal and Compliance Considerations for Executing from Beginning to End Amid Ongoing Scrutiny,” 27th Pharmaceutical and Medical Device Ethics and Compliance Congress, 10/14/2026
- “State and Federal Transparency Developments—Navigating Varied and Evolving Requirements,” Informa Transparency & HCP Engagement 2026, 8/11/2026
- “Highlights from Recent Enforcement and Related Healthcare Compliance Developments,” Porzio's Pharma & Medtech Symposium, 6/02/2026
- “Guardrails for Evolving Field Facing Roles,” Pharmaceutical Compliance Congress (PCC), 4/29/2026
- "Social Media, Influencers and Digital Opinion Leaders (DOLs)," Informa Connect, Pharmaceutical Compliance Congress, 4/30/2025
- "Payments to Third Parties: Non-Traditional Arrangements and Related Compliance Considerations," Porzio Webinar, 3/04/2025
- "Clinical and R&D Compliance –Emerging Trends and New Risk Areas," Informa Pharmaceutical Compliance Congress, 4/16/2024
- "Assessing Compliance Priorities: Considerations for Conducting an Effective and Collaborative Compliance Risk Assessment," 24th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, 10/25/2023

Media Mentions

- "Drug Cos. Face Persistent Scrutiny Over Physician Kickbacks," *Law360*, 6/10/2025
- "The '3 Fs' of social media compliance scrutiny," *Informa Connect Compliance & Legal, Biotech & Pharma*, 6/05/2025

Practices

- Life Sciences Legal, Regulatory & Compliance

Area of Focus

- Compliance & Regulatory Counseling
- Pharmaceutical, Medical Device & Biotech

Industries

- Life Sciences

Industry Focus Areas

- Medical Device
- Pharmaceutical

Bar Admissions

- Connecticut, 2009
- Massachusetts, 2021
- New York, 2009
- New Jersey, 2010

Education

- *Seton Hall Law School*
  U.S. Healthcare Compliance Certification, 2017
- *New England Law*
  J.D., 2008
- *Lafayette College*
  B.A., 2004